Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National, Phase II/III, Multicenter, Randomized, Double-blind, Controlled, Parallel,Effect of Melatonin 3mg and 5mg Plus Cognitive Behavioral Therapy for Insomnia (CBT-I) Compared to the CBT-I Alone in the Treatment of Insomnia Disorder

NCT02798367 is registered in ClinicalTrials.gov with Ache Laboratorios Farmaceuticos S.A. as lead sponsor.

NCT NCT02798367
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02798367 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National, Phase II/III, Multicenter, Randomized, Double-blind, Controlled, Parallel,Effect of Melatonin 3mg and 5mg Plus Cognitive Behavioral Therapy for Insomnia (CBT-I) Compared to the CBT-I Alone in the Treatment of Insomnia Disorder
Lead sponsor
Ache Laboratorios Farmaceuticos S.A.
Phase
Phase 2/3
Overall status
Unknown status
Start date
March 22, 2018
Completion date
November 30, 2021
Enrollment
307 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

insomnia disorder